At Holy Redeemer Bott Cancer Center, we're always looking for better ways to prevent, diagnose and treat cancer. Our participation in clinical trials furthers our knowledge and gives you the opportunity to contribute to the advancement of cancer care, while receiving the latest treatment options from clinical experts.
People participate in clinical trials with hope for:
- A new, effective treatment
- Extending life
- Relieving pain or other symptoms
- Contributing to advances that will help others
If you are eligible for a clinical trial, the choice to participate is always yours. We encourage you to discuss participation with your family members and physician.
Clinical research — research studies with people — is essential before making a new cancer treatment widely available to the general public.
Our Institutional Review Board of highly qualified physicians, pharmacists and others thoroughly reviews each clinical trial, applying the strictest quality standards to protect the well-being of our volunteer participants.
Past clinical trials have taught us much of what we know about cancer and its treatment. Volunteers in current clinical trials are paving the way for tomorrow’s cancer prevention, diagnosis and treatments. We are grateful to the many people who have contributed to our enhanced knowledge.
Through our membership in the Sidney Kimmel Cancer Network at Jefferson, we offer you access to national clinical trials with promising new treatments.
We have access to:
- Trials sponsored by the National Cancer Institute
- Select trials supported by the National Institutes of Health, developed by researchers at Jefferson
Each trial has its own guidelines for eligibility. Speak to your doctor or contact Holy Redeemer Bott Cancer Center to find out if we offer a trial that is right for you. Call us at 215-938-3551.
Collapse all | Expand all
ECOG 2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in patients with Metastatic Breast Cancer.
This study compares a different treatment approach for breast cancer, which has spread beyond the breast to other parts of the body with the standard or usual treatment.
NSABP B51/RTOG 1304: A Randomized Phase III Clinical Trial evaluating Post-Mastectomy Chest Wall, Regional Node XRT and Post-Lumpectomy Regional Nodal XRT in patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy.
This study compares if the addition of chest wall + regional nodal XRT after mastectomy or the regional nodal XRT, in addition to breast XRT after breast conserving surgery, will significantly reduce the rate of events for invasive breast cancer recurrence-free intervals in patients who initially have confirmed positive biopsy axillary nodes, but convert to negative axillary nodes following neoadjuvant chemotherapy.
A011202: A Randomized Phase III Trial comparing Axillary Lymph Node Dissection to Axillary Radiation in breast cancer patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy.
This study compares whether removing some of the lymph nodes from the arm pit, but not removing them all, followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes from the arm pit removed during breast surgery followed with radiation (standard of care).
S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)—associated Musculoskeletal Symptoms in women with early stage breast cancer.
This study compares the effects, good and/or bad, of the medication duloxetine compared to placebo (contains no active ingredient) on your joint pain that is associated with taking aromatase inhibitors. Duloxetine is a drug usually prescribed to treat depression or anxiety, pain caused by nerve damage or fibromyalgia (a painful muscle/bone/nerve disorder) and a muscle and bone pain from a type of arthritis. Researchers on this study want to see if the pain relieving effects of the drug work for your type of pain.
CALGB 30610: A Phase III Comparison of Thoracic Radiotherapy Regimens in patients with Limited Small Cell Lung Cancer also receiving Cisplatin and Etoposide.
This study looks at 2 different ways to give radiation therapy for patients with limited stage small cell lung cancer that has not been detected outside the chest.
Lung Cancer Screening Program Using Low Dose CT Scan with Prospective Patient Outcome Data Collection: The National Cancer Institute (NCI) conducted a large national lung screening trial (NLST), which showed a benefit in detecting lung cancer earlier in heavy smokers using LDCT. Essentially, it comes down to how long and how much you have smoked in your lifetime. At this time, most insurance does not cover this scan and there is a cost ($289); however, this test can be very valuable in detecting early stage lung cancer, when it is most treatable.
For more information, call 215-938-LUNG or click here.
For more information on Clinical Trials, please visit the following websites:
National Cancer Institute